1. The in vitro and in vivo efficacy of CT-P59 against Gamma, Delta and its associated variants of SARS-CoV-2
- Author
-
Hanmi Noh, Jong-In Kim, Ji-Min Seo, Manki Song, Minho Lee, Sang-Seok Oh, Hyo-Young Chung, Sun-Je Woo, Carel A. van Baalen, Eunji Yang, Soo Young Lee, Dong Kyun Ryu, Patricia M. Nuijten, Ki-Sung Kwon, Su-Kyeong Eo, Bobin Kang, Minsoo Kim, Gippeum Lim, Seong-Gyu Kim, Jung-ah Choi, Aloys Sl. Tijsma, and Cheol-Min Kim
- Subjects
CT-P59 ,Regdanvimab ,Cell ,Biophysics ,Mice, Transgenic ,Biology ,Antibodies, Monoclonal, Humanized ,Antiviral Agents ,Biochemistry ,Article ,Virus ,Neutralization ,Therapeutic antibody ,In vivo ,medicine ,Animals ,Humans ,Potency ,Gamma ,Molecular Biology ,SARS-CoV-2 ,Body Weight ,COVID-19 ,Cell Biology ,Antibodies, Neutralizing ,Survival Analysis ,Virology ,In vitro ,COVID-19 Drug Treatment ,SARS-CoV-2 variant ,Disease Models, Animal ,medicine.anatomical_structure ,Delta ,Immunoglobulin G ,Female ,Animal studies ,Respiratory tract - Abstract
The SARS-CoV-2 variant is rapidly spreading across the world and causes to resurge infections. We previously reported that CT-P59 presented its in vivo potency against Beta variants, despite its reduced activity in cell experiments. Yet, it remains uncertain to exert the antiviral effect of CT-P59 on Gamma, Delta and its associated variants (L452R). To tackle this question, we carried out cell tests and animal studies. CT-P59 showed neutralization against Gamma, Delta, Epsilon, and Kappa variants in cells, with reduced susceptibility. The mouse challenge experiments with Gamma and Delta variants substantiated in vivo potency of CT-P59 showing symptom remission and virus abrogation in the respiratory tract. Collectively, cell and animal studies showed that CT-P59 is effective against Gamma and Delta variants infection, hinting that CT-P59 has therapeutic potential for patients infected with Gamma, Delta and its associated variants.
- Published
- 2021